anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To provide an injection soln. which contains the salt of dichlofenac, may be stably stored over a long period of time of several months without a change in pH in spite of thermal sterilization and allows parenteral medication. CONSTITUTION: The salt of the dichlofenac and 1,2-propylene glycol or polyethylene glycol 300-400 as a dissolving agent, glutathione or N-acetylcysteine which is a stabilizer and further, a liquid carrier for injection prepn. are incorporated as effective components into this soln. The soln. is useful for an inflammatory state entailing pain, more particularly a rheumatic treatment and the dose thereof is 25 to 100 mg/day. The glutathione prepd. by combining a 2 to 3C alkanecarboxylic acid 2 to 4C alkyl ester and hydroxy 2 to 4C alkanecarboxylic acid 2 to 4C alkyl ester or N-acetylcysteine is used as the glutathione to be used as the stabilizer.
Sunitinib malate can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with sunitinib malate. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with sunitinib malate for advanced RCC (Study 3) and GIST (Study 1) (n=577) and in approximately 10% of the patients treated with sunitinib malate for pNET (Study 6) (n=83). For patients being treated with sunitinib malate for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes.  
  
Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of sunitinib malate. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia.
Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug Nebulized Sodium Nitrite (AIR001) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Placebo instead of AIR001.
BACKGROUND: Bowel preparation (BP) for colonoscopy induces significant changes in gut microbiota, causing dysbiosis that, in turn, elicits intestinal symptoms. Consequently, probiotics may counterbalance the disturbed microbiota after BP. So, probiotics may restore microbiota homeostasis.
METHODS: The current study evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions living cells), and Lactobacillus delbrueckii LDD01 (200 millions living cells), Patients were randomized in two groups (2:1). Group A took one stick/daily for four weeks after colonoscopy. Group B was considered as control. Patients were evaluated at baseline (T0) and after one (T1), two (T2), and four (T3) weeks. The severity of symptoms was measured by patients using a Visual Analog Scale.
RESULTS: Abincol® significantly diminished the presence and the severity of intestinal symptoms at T2 and even more at T3. All patients well tolerated the probiotic mixture.
CONCLUSIONS: The present study suggests that Abincol® may be considered an effective and safe therapeutic option in managing patients undergoing BP. The course should last one month.
FIELD: medicine, ophthalmology, endocrinology. SUBSTANCE: catheter is fitted into orbit cavity and medicinal agents are administrated through this catheter into lymphatic region of orbit. Firstly, lymphostimulating agents are administrated, mainly lidocaine and lydazum. Then curative mixture containing 10-30 mg of glutoxim, 30 000-90 000 cells/ml of autolymphocytes in 6-8 ml of physiological solution is administrated. Administration of mixture is carried out 2-3 times with interval for 48-72 h. Prepared autolymphocytes can be activated by incubation of cells with 10-20 mg of glutoxim for 40-60 min at temperature 24-26 C. Method provides the enhancement of visual functions due to acceleration of reparative and metabolic processes and enhancement of immunologic reactivity of body. Invention can be used for treatment of patients with diabetic retinopathy. EFFECT: enhanced effectiveness of treatment. 4 cl, 2 ex
Patients in Cohort I, Arm B receive standard of care therapy and receive AEO PO BID for 1 month on study. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
BACKGROUND: Gastroesophageal cancer is a major cause of cancer-related mortality worldwide. Treatment of both early stage and advanced disease remains highly reliant on cytotoxic chemotherapy. About 4-24% of gastroesophageal cancers are microsatellite instability high (MSI-H). The MSI-H subtype is associated with favorable prognosis, resistance to cytotoxic chemotherapy, and sensitivity to immune checkpoint inhibitors (ICI). Recent studies have demonstrated promising activity of ICIs in the MSI-H subtype, resulting in fundamental changes in the management of MSI-H gastroesophageal adenocarcinoma.
PURPOSE: In this review, we discuss the prevalence, characteristics, prognosis, and management of MSI-H gastroesophageal adenocarcinoma, with a focus on recent and ongoing studies that have changed the landscape of treatment for the MSI-H subtype. We also discuss current challenges in the management of resectable and advanced MSI-H gastroesophageal cancer, including the need for more accurate biomarkers of response to ICI therapy.
PURPOSE:To obtain the titled novel substance having immune activating action and low side effect, by extracting a mold of bacterium belonging to the genus Fusobacterium with a dialkyl sulfoxide. CONSTITUTION:A mold of a bacterium belonging to the genus Fusobacterium is extracted with a dialkyl sulooxide, a hydrophilic organic solvent (e.g., acetone) is added to the preferably prepared extracted solution to give a precipitate, which is subjected to removal of protein by enzymatic treatment with pronase, and it is subjected to ultrafiltration using a filter membrane having 50,000- 200,000 fraction molecular weight, to give novel carcinostatic substance TF- 500 or its salt having the following properties. Appearance: white gray or light brown powder. Melting point: 180 deg.C (decomposition)-195 deg.C. Solubility: soluble in water, insoluble in methanol, etc. Positive in Molish, phenol sulfate, indole hydrochloride reaction, etc. Elemental analysis (%): C 38-47, H 5-7, N 1-4.
A dicing device dices tissue harvested from a patient. The dicing device comprises a grid cutting element and a tray to receive diced tissue. The dicing device may be integrated into an otherwise conventional biopsy device. The diced tissue specimens may be further processed, such as by being introduced into a self-expanding fistula plug creation and delivery system. The self-expanding fistula plug creation and delivery system comprises a sheet and a reinforcement tube. A scaffold material may be placed in the sheet, which may then be folded and reinforced, with the scaffold material being compressed in the sheet. The scaffold material may then be pushed into a catheter end. The catheter end may be inserted in a fistula. The scaffold material may then be flushed with a cell matrix that is based on the diced tissue to create a fistula plug, which may be left in the fistula.
OBJECTIVE: To identify important MRI features to differentiate hepatic mucinous cystic neoplasms (MCN) from septated hepatic cysts (HC) using random forest and compared with logistic regression algorithm.
METHODS: Pathologically diagnosed hepatic cysts and hepatic MCNs with pre-operative contrast-enhanced MRI in our hospital from 2010 to 2023 were collected and only septated lesions on enhanced MRI were enrolled. A total of 21 septated HC and 18 MCNs were included in this study. Eighteen MRI features were analyzed and top important features were identified based on random forest (RF) algorithm. The results were evaluated by the prediction performance of a RF model combining the important features and compared with the performance of the logistic regression (LR) algorithm. Finally, for each identified feature, diagnostic probability, sensitivity, and specificity were calculated and compared.
RESULTS: Four variables, i.e., the septation arising from wall without indentation, multiseptate, intracapsular cyst sign, and solitary lesion were extracted as top important features with significance for MCNs by the random forest algorithm. The RF model using these variables had an AUC of 0.982 (0.95CI, 0.950-1.000), compared with the LR model based on two identified features with AUC of 0.931 (0.95CI, 0.846-1.000), p = 0.202. Among the four important features, multiseptate had the highest specificity (95.2%) and good sensitivity (72.2%, lower than the septation from wall without indentation, 94.4%) to diagnose MCNs.
CONCLUSION: Four out of 18 MRI features were extracted as reliably important factors to differ hepatic MCNs from septated HC. The combination of these four features in a RF model could achieve satisfactory diagnostic efficacy.
FIELD: medicine.SUBSTANCE: group of inventions relates to medical equipment, specifically to pressure maintenance system (10) and electronic data medium. System (10) is configured to adjust parameters of flow of respiratory gas under pressure, supplied to subject (12). System comprises pressure generator (14) configured to generate a respiratory gas flow under pressure to be supplied to an individual's respiratory tract. System includes humidifier (16) configured to humidify the flow of respiratory gas under pressure. System has sensors (18) configured to generate output signals carrying information relating to parameters of the flow of pressurized breathing gas. System comprises user interface (20) configured to receive feedback information from a subject indicating a comfort level with respect to the flow of pressurized breathing gas. System includes physical computer processors (22) which, owing to computer-readable instructions, are configured to control a pressure generator and a humidifier for feeding a respiratory gas flow under pressure to a subject, in accordance with a preset therapeutic mode, based on the output signals. Processors are configured to receive feedback information input through a user interface. Processors are configured to perform automatic control of flow of respiratory gas under pressure to increase comfort level of the subject. Automatic adjustment is based on received feedback information and output signals and includes adjustment of pressure and/or humidifier generator. Due to computer-readable instructions, processors (22) are additionally configured to receive additional feedback information introduced through the user interface after automatic adjustment. Processors are configured to provide a subject with a hint through a user interface for manual adjustment of a pressure generator, a humidifier or an ambient environment based on additional feedback information. Electronic data medium contains computer-readable instructions stored in electronic form, which, when executing a computer program, cause physical computer processors (22) to function.EFFECT: technical result is user feedback through user interface on operating condition of system and ambient conditions.11 cl, 4 dwg
The present invention discloses a medicament spraying agent for treating the disease of a throat and an oral cavity. Solidago, honeysuckle flower, cyrtomium rhizome, forsythia, wild mint, epazote and blumea balsamifera are used as main raw materials, and are prepared from a preparation method of a conventional medicament spraying agent. The medicament spraying agent is a medicament prepared according to a seedling medicine theory. The medicament adopts a Chinese medicinal material which is abundant in a place as a raw material. The medicament spraying agent has low cost, the functions of heat clearing, detoxifcation, wind and heat dispelling and throat clearing, and a favorable therapeutic effect. The medicament spraying agent has the characteristics of easy operation, low cost and good therapeutic effect. The medicament spraying agent can be used for the treatment of disease of upper respiratory tract infection, acute pharyngolaryngitis, chronic pharyngolaryngitis, stomatitis, swelling and aching of gums, halitosis, etc.
Insomnia is a prevalent health concern which is often associated with functional impairments, reduced quality of life, and increased health-care costs. The proposed study may provide useful information about optimal models for integrating behavioral and pharmacological therapies for the clinical management of insomnia.

Participants are randomly assigned to CBT or CBT plus medication. After the 6-week acute treatment phase, participants enter into a 6-month extended treatment phase. Of those treated with CBT alone initially, responders are randomized to extended CBT or no treatment. Of those receiving the combined CBT plus medication approach initially, responders are randomized to an extended treatment consisting of either CBT plus medication (used on an as needed schedule) or CBT alone (plus medication tapering). Outcome is evaluated across measures of sleep, clinical ratings, and several indices of daytime functioning. The measures are administered at baseline, at the end of the acute and extended treatment phases, and at 6, 12, and 24-month follow-up.
We propose to adapt the Teen Marijuana Check Up for persistent cannabis users with FEP in CSC. Dr. Walker, the developer of the TMCU, will be a consultant. Adaptations will include tailoring content of assessment and feedback to risks of persistent cannabis use in FEP, providing education on lower risk cannabis use, and adding a session to address collaborative planning to maintain CSC engagement and antipsychotic adherence and to reduce harm associated with cannabis use. We will also develop guidelines for integrating continued collaborative, harm-reduction focused discussion of cannabis use into CSC, consider adding booster or check-in sessions, and specify how family members can be brought into the check-up process. To inform these adaptations, we will collect quantitative data from cannabis-using FEP patients (n of 40) and conduct qualitative interviews with cannabis-using patients, family members, and CSC clinicians (15 of each) about their perspectives on cannabis use and CSC participation (Aim 1). We will use these data as part of an iterative process to specify the adapted intervention that will integrate information gathered from team discussion and focus groups with FEP patients and family members and vetting of intervention components by key stakeholders (Aim 2). Finally, we will conduct a pilot of the adapted intervention (n of 40 cannabis-using FEP patients compared to matched controls) to examine feasibility, acceptability, fidelity, and preliminary impact on intervention targets and outcomes (Aim 3). If results are promising, the intervention can be tested in a large RCT across the EPINET.
Apart from receiving scheduled medical follow-up, the subjects in the experimental group will receive a weekly 45-minute lesson on musical training for 52 weeks. The musical training will be conducted by the Music Children Foundation and be implemented in a ratio of one subject to one qualified orchestral performer at the subjects' homes. A musical instrument will be assigned to each subject based on their interests and the results of the prior assessment of subjects' expiratory function and fine motor skills. The musical training will start at the lowest level, such as hitting simple notes and end at the highest level, such as playing an entire song.
PURPOSE:To separate the components of blood efficiently, by making the boold flow continuously at a suitable rising angle in the flow direction thereof, and transferring the blood stream to a multilayered stream consisting of the component layers. CONSTITUTION:Blood is separated into the components thereof by the settling action of the gravity.. In the process, the blood is made to flow through a blood path 2 at a rising angle >=10 degrees and <=45 degrees in the flow direction of the blood. The depth of the blood stream is 0.2-20mm., preferably 0.2-10mm. and the linear velocity of the blood stream is 0.5-200mm./min, preferably 1-100mm./ min. The blood stream is desirably kept at 30-42 deg.C,preferably 37-40 deg.C. The blood under the conditions described above is made to flow from a blood introductory path 3 to give the desired components of the blood from discharge paths 6 and 7 for separated components. The material of a closed vessel is required to be a hard nontoxic and antithrombotic material without changing by the internal pressure, e.g. polycarbonate resin.
PURPOSE:To produce a solid solution preparation of carmofur, soluble rapidly in the stomach, absorbed through the upper duodenum in high efficiency, and having high bioavailability, by converting carmofur (an anti-malignant tumor agent) to a solid solution with a water-soluble polymer. CONSTITUTION:Carmofur (1-hexylcarbamoyl-5-fluorouracil) is mixed with a water- soluble polymer (e.g. PVP, MC, CMC, etc.), and dissolved completely in an organic solvent (e.g. methanol, ethanol, etc.). The solvent is evaporated by vacuum distillation, and the residue is dried under reduced pressure to obtain the objective solid solution preparation. Although carmofur has low rate of dissolution, and is unstable at the middle or lower part of the small intestine having neutral nature, the preparation can be dissolved rapidly under acidic condition in the stomach, and absorbed through the upper duodenum. Accordingly, the absorbability and the bioavailability of the carmofur can be improved.
Patients receive cycles 1-2 of the DD-4A regimen as in STAGE II FHWT and STAGE III FHWT Arm II above. Patients receive cycles 3-4 of the M regimen as in STAGE III FHWT Arm IIB above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
The invention provides for water-dispersible microparticles comprising magnetic material and organic substance, such as a pharmaceutical or a pigment, that constitute in totality at least 50%, or preferably more that 70%, of the dry mass of the particle. The method of making such microparticles is also provided, comprising coating of the magneitc material in an aqueous colloid form with a layer of a polyelectrolyte. and combining the coated colloid with the organic substance having ionic charge opposite to that of the polyelectrolyte. When the organic substance is poorly soluble in water, the combining comprises dissolving of the substance in a water-miscible organic solvent, and combining said solution with the polyelectrolyte-coated magnetic colloid. The magnetic pharmaceutical microparticles are useful for magnetically- guided drug delivery, and/or for non-invasive monitoring of the drug distribution in the body. Magnetic microparticles comprising dyes and pigments are useful in magnetic inks.
Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.
PURPOSE: To evaluate the microstructural optical coherence tomography and fundus autofluorescence imaging predictors of visual acuity, metamorphopsia, and aniseikonia following rhegmatogenous retinal detachment repair.
METHODS: This is a multicenter retrospective study of patients with primary rhegmatogenous retinal detachment who underwent repair. Best-corrected visual acuity, metamorphopsia, and aniseikonia were formally tested at 3 months postoperatively. Metamorphopsia and aniseikonia were quantitatively assessed with M-CHARTS and the New Aniseikonia Test, respectively. High-resolution spectral-domain optical coherence tomography and fundus autofluorescence images were obtained at 3 months postoperatively. Images were assessed for discontinuity of the outer retinal bands on optical coherence tomography and retinal displacement detected by retinal vessel printings on fundus autofluorescence by two masked graders with disagreements adjudicated by a third senior masked grader. Multiple linear regression models were used to determine the predictors of postoperative visual acuity, metamorphopsia, and aniseikonia.
RESULTS: Six hundred fourteen eyes of 614 patients were included in this study. Regression analysis indicated that significant early postoperative (at 3 months) imaging predictors of visual acuity were discontinuity of the external limiting membrane (P = 0.001) and the presence of retinal vessel printings on fundus autofluorescence (P = 0.033). Discontinuity of interdigitation zone was a significant predictor of metamorphopsia [horizontal metamorphopsia (P =0.004); vertical metamorphopsia (P = 0.056); average of horizontal metamorphopsia + vertical metamorphopsia (P = 0.008)], and presence of retinal vessel printings was a significant predictor of aniseikonia (P = 0.04).
CONCLUSION: Discontinuity of the external limiting membrane and retinal displacement were significant predictors of postoperative visual acuity following rhegmatogenous retinal detachment repair. Discontinuity of the interdigitation zone and retinal displacement were significant predictors of metamorphopsia and aniseikonia, respectively.
The invention provides a fresh mulberry leaf face soap, and belongs to the technical field of household chemicals. The soap is made from fresh mulberry leaf extract, glycerol, palm oil, soap flakes, higher fatty acid, triethanolamine and deionized water according to a certain weight ratio. The invention retains the nutrition of fresh mulberry leaves. The fresh mulberry leaf face soap of the present invention can be directly applied to clean face, has the functions of deep cleansing for facial skin, softening horniness, fading melanin, diminishing inflammation, inhibiting bacteria, nourishing skin, balancing oil secretion, promoting facial blood circulation, improving skin quality, etc., has no side effects, and is suitable for all kinds of skins of the crowd. The soap uses the fresh mulberry leaf extract, which is pure natural plant juice and has no stimulation to the skin. The used water after washing can be directly used for watering flowers and plants. The soap is a facial washing protection product which can be used for a long time.
An efficient method for therapeutic treatment of leukemia is provided in which a patient's body fluid during external circulation is brought into direct contact with an adsorbent material capable of specifically and selectively adsorbing leukemic cells in the body fluid. The leukemic cell-adsorbing material is a composite of a lectin protein coupled with a physiologically inert carrier material such as a galactan polysaccharide in the form of beads. The lectin protein may be obtained from a mushroom fungus such as  Agrocybe cylindracea  or a leguminous seed such as from the jequirity bean plant. The lectin protein and carrier material can be bound by forming chemical linkages between amino groups in the lectin protein and functional groups in the carrier material, and unreacted functional groups of the carrier material may be blocked with an amino acid. A leukemic cell-adsorbing column may be formed by filling the leukemic cell-adsorbing material into a tubular body to form an adsorbent bed. The tubular body may have an inner diameter of from 10 to 20 mm and a height of from 50 to 200 mm.